Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Aimmune Therapeutics Inc    AIMT

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
39(c) 38.65(c) 39.43(c) 37.97(c) 37.83(c) Last
292 151 357 030 370 464 475 167 813 317 Volume
+1.80% -0.90% +2.02% -3.70% -0.37% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -128 M
Net income 2017 -127 M
Finance 2017 103 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -160 M
Net income 2018 -162 M
Finance 2018 22,3 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 1 924 M
More Financials
Company
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company.It engages in the research and development of desensitization treatments for peanut and other food allergies.The company's portfolio includes the characterized oral desensitization immunotherapy system.Its pipeline consists... 
Sector
Pharmaceuticals
Calendar
05/21Earnings Release
More about the company
Surperformance© ratings of Aimmune Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on AIMMUNE THERAPEUTICS INC
01/10 AIMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregis..
01/10 AIMMUNE THERAPEUTICS : Broadens and Extends Supply Agreement With Golden Peanut ..
01/08 AIMMUNE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (fo..
01/08 AIMMUNE THERAPEUTICS : Announces 2018 Outlook, Including Upcoming Data from Pivo..
01/03 AIMMUNE THERAPEUTICS : to Present at the 36th Annual J.P. Morgan Healthcare Conf..
01/01 INSIDER TRADING ACTIVITY AIMMUNE THE : AIMT) – Insider Sold 3,283 shares o..
2017 AIMMUNE THERAPEUTICS : to Participate in the BMO Capital Markets 2017 Prescripti..
2017 ANAPTYSBIO : Peanut Allergy- Highly Potential Market for Upcoming Therapies
2017 AIMMUNE THERAPEUTICS : to Participate in the BMO Capital Markets 2017 Prescripti..
2017 AIMMUNE THERAPEUTICS : to Host Investor Symposium on Peanut Allergy Treatment wi..
More news
Sector news : Specialty & Advanced Pharmaceuticals
01/17 TSX ends up as banks lead rally after rate hike
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/17 EXCLUSIVE : J&J attracts Chinese interest for diabetes business in potential $3-..
01/17 Allergan Pact Advances -- WSJ
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
01/15Aimmune Therapeutics $AIMT Given a $45.00 Price Target at Credit Suisse Group.. 
01/11Credit Suisse Reaffirms Their Buy Rating on Aimmune Therapeutics $AIMT  
01/11“The hardest thing for us to make is the first dose,” says $AIMT Ceo Dillly. ..
3
01/11Zacks Investment Research Downgrades Aimmune Therapeutics $AIMT to Sell
1
01/10$AIMT: Aimmune Therapeutics announced an expansion and extension of its exclu.. 
More tweets
Qtime:45
News from SeekingAlpha
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
2017 YOUR DAILY PHARMA SCOOP : Aeterna Zentaris Gets FDA Nod, Valeant Finalizes Sprou..
2017 Premarket analyst action - healthcare
2017 Aimmune Therapeutics - Desensitize Yourself For A Good Bet!
2017 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
Chart AIMMUNE THERAPEUTICS INC
Duration : Period :
Aimmune Therapeutics Inc Technical Analysis Chart | AIMT | US00900T1079 | 4-Traders
Technical analysis trends AIMMUNE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 55,5 $
Spread / Average Target 47%
EPS Revisions
Managers
NameTitle
Stephen George Dilly President, Chief Executive Officer & Director
Mark D. McDade Chairman
Jeffrey H. Knapp Chief Operating Officer
Eric H. Bjerkholt Chief Financial Officer
Daniel C. Adelman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS INC0.03%1 931
ABBVIE5.98%163 379
MERCK KGAA1.86%14 691
KYOWA HAKKO KIRIN CO LTD-1.98%11 433
JAZZ PHARMACEUTICALS PLC11.25%8 981
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD14.67%7 028